@article{TCR13588,
author = {Santiago Viteri and Rafael Rosell},
title = {Ceritinib and cabozantinib: new tyrosine kinase inhibitors improve treatment options for non-small cell lung cancer patients},
journal = {Translational Cancer Research},
volume = {6},
number = {Suppl 3},
year = {2017},
keywords = {},
abstract = {In The Lancet, Jean Charles Soria and colleagues presented the results of the ASCEND-4 study: a randomized phase 3 trial comparing ceritinib against platinum doublet chemotherapy as first line treatment for non-small cell lung cancer (NSCLC) patients harboring anaplastic lymphoma kinase (ALK) rearrangements that included 376 patients (189 in the ceritinib arm and 187 in the chemotherapy arm) (1).},
issn = {2219-6803}, url = {https://tcr.amegroups.org/article/view/13588}
}